Dublin, March 28, 2017 -- Research and Markets has announced the addition of the "Global Psoriasis Drugs Market by Drug Molecule (Biologic, Small Molecule Drugs), By Route of Administration (Systemic, Topical), By Mechanism of Action (TNF Inhibitors, Interleukin Blockers) Outlook 2022" report to their offering.
According to World Health Organization, the prevalence of psoriasis in different countries ranges between 0.09% and 11.4%. Treatment of this disease is based on controlling of its symptoms. Topical and systemic therapy drugs are used in combination, in order to combat this disease.
As per the report Global Psoriasis Drugs Market by Drug Molecule (Biologic, Small Molecule Drugs), By Route of Administration (Systemic, Topical), By Mechanism of Action (TNF Inhibitors, Interleukin Blockers) Outlook 2022, the global psoriasis drugs market is anticipated to witness a high growth during 2016-2022. This report provides a detailed analysis of the current and future market scenario of the global psoriasis drugs market. The report provides insight about the major drivers and challenges, along with the latest innovations in this industry. In addition, the report also highlights various opportunities available for growth of the global psoriasis drugs market.
The global psoriasis drugs market has been segmented on the basis of type of drug molecule into biologics drugs and small molecule/chemical drugs. Biologics are gaining popularity due to the high efficacy and specificity of these drugs for the treatment of various types of psoriasis. Moreover, the increasing awareness about these drugs among people is also helping its market to grow all across the globe.
Furthermore, the global psoriasis drugs market has also been segmented on the basis of their route of administration. According to the report, the psoriasis drugs can be administered by topical route as well as systemic route. Systemic route of administration is expected to witness a high growth owing to its high efficacy. Similarly, the market has been segmented on the basis of mechanism of action of the drug into TNF inhibitors, interleukin blockers, and others. Interleukin blockers are gaining high popularity amongst all classes of drugs.
Key Topics Covered:
1. Analyst View
2. Research Methodology
3. Psoriasis: An Overview
4. Market Dynamics
4.1 Drivers
4.1.1 Rising Prevalence of Psoriasis
4.1.2 Increasing Awareness
4.1.3 Growing Geriatric Population
4.1.4 Rising Healthcare Expenditure
4.2 Challenges
4.2.1 Patent Cliff of Blockbuster Drugs
4.2.2 High Cost
4.3 Opportunities
4.3.1 Biologic Drugs Flaring Up Psoriasis Drugs Market
4.3.2 Incessant Launch of Novel Products
5. Global Psoriasis Drugs Market Outlook 2022
6. Market Segmentation by Type of Drug Molecule
6.1 Biologic Drugs
6.2 Small Molecule/Chemical Drugs
7. Market Segmentation by Route of Administration
7.1 Systemic
7.2 Topical
8. Market Segmentation by Mechanism of Action
8.1 TNF Inhibitors
8.2 Interleukin Blockers
8.3 Others
9. Market Segmentation by Geography
9.1 North America
9.2 Europe
9.3 Asia-Pacific
10. Trends & Developments
10.1 Interleukin Inhibitors Driving Psoriasis Drugs Market
10.2 TNF-alpha Blockers for the Treatment of Psoriasis
11. Mergers, Acquisitions & Collaborations
12. Pipeline Analysis
13. Porter's Five Forces Analysis
14. Key Players
14.1 AbbVie Inc.
14.2 Biocon
14.3 Pfizer Inc.
14.4 Novartis
14.5 Eli Lilly and Company
14.6 Celltrion Inc.
14.7 Celgene Corporation
14.8 Johnson & Johnson
14.9 Dr.Reddy's Laboratories
14.10 Amgen Inc.
For more information about this report visit http://www.researchandmarkets.com/research/d3d8zn/global_psoriasis
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs, Immune Disorders Drugs, Psoriasis Drugs


Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Washington Post Publisher Will Lewis Steps Down After Layoffs
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 



